This real-world cohort study demonstrated that biological therapy with anti-IL-5 and anti-IL-5R monoclonal antibodies is effective in improving clinical asthma control, quality of life, and lung function in patients with severe eosinophilic asthma who do not respond to conventional treatment. The gene discussed is IL5; the disease is asthma.